2,3-二氢-1H-茚-5-乙酸 | 5453-98-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 2,3-二氢-1H-茚-5-乙酸
• 英文名称: indan-5-yl acetic acid
• 英文别名: indan-5-acetic acid；indan-5-yl-acetic acid；Indan-5-yl-essigsaeure；2,3-dihydro-(1H)-inden-5-yl acetic acid；5-indaneacetic acid；2,3-Dihydro-1h-inden-5-ylacetic acid；2-(2,3-dihydro-1H-inden-5-yl)acetic acid
• CAS: 5453-98-5
• 化学式: C₁₁H₁₂O₂
• mdl: MFCD06378266
• 分子量: 176.215
• InChiKey: AVLCYTRBQULWGZ-UHFFFAOYSA-N

物化性质

• 熔点：
  113-114 °C
• 沸点：
  333.0±11.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  2,3-二氢-1H-茚-5-乙酸 在 sodium amide 作用下， 生成 1-indan-5-yl-cyclopent-3-enecarboxylic acid
  参考文献：
  名称：

  US2573015

  摘要：

  公开号：
• 作为产物：
  描述：

  indan-5-yl-acetic acid ethyl ester 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 15.0h， 生成 2,3-二氢-1H-茚-5-乙酸
  参考文献：
  名称：

  发现茚满丙烷酰胺作为有效的和选择性的TRPV1拮抗剂。

  摘要：

  研究了一系列的茚满型乙酰胺和丙酰胺类似物作为TRPV1拮抗剂。结构-活性关系的分析表明，与相应的2，3-二氢苯并呋喃和1，3-苯并二恶唑替代物相比，茚满A-区类似物表现出更好的拮抗作用。其中，拮抗剂36对hTRPV1和mTRPV1表现出对辣椒素的强效和选择性拮抗作用。此外，体内研究表明，拮抗剂36在福尔马林小鼠疼痛模型的两个阶段均显示出优异的镇痛活性，并且在第二阶段以1 mg / kg的剂量完全抑制了疼痛行为。

  DOI：

  10.1016/j.bmcl.2019.126838

文献信息

• Silver(I)/persulfate oxidative decarboxylation of carboxylic acids. Arylacetic acid dimerization.
  作者：William.E. Fristad、Jeffrey A. Klang

  DOI：10.1016/s0040-4039(00)81888-2

  日期：1983.1

  The oxidative decarboxylation of arylacetic acids by sodium persulfate and a catalytic amount of silver nitrate produces benzylic radicals which dimerize cleanly to give 1,2-diarylethanes.

  过硫酸钠和催化量的硝酸银对芳基丙烯酸的氧化脱羧作用产生苄基，该苄基可干净地二聚而得到1,2-二芳基乙烷。
• Azacyclic compounds and their use as analgesic agents
  申请人：Dr. Lo. Zambeletti S.p.A.

  公开号：US04994450A1

  公开（公告）日：1991-02-19

  A compound, or a solvate or salt thereof, of formula (I) ##STR1## in which: R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl or C.sub.4-12 cycloalkylalkyl groups, or together form a C.sub.2-8 branched or linear polymethylene or C.sub.2-6 alkenylene group optionally substituted with a hetero-atom, provided that R.sub.1 and R.sub.2 are not simultaneously hydrogen; R.sub.3 is hydrogen, C.sub.1-6 alkyl, preferably methyl or ethyl, or phenyl, or R.sub.3 together with R.sub.1 form a --(CH.sub.2).sub.3 -- or --(CH.sub.2).sub.4 -- group; p is 1, 2, 3 or 4, and R is a group of formula (II) ##STR2## in which the group --(CHR.sub.4).sub.n --X-- is in the meta- or para-position with respect to YR.sub.5 or R.sub.6, R.sub.4 is hydrogen or C.sub.1-6 alkyl, preferably hydrogen; n is 0, 1 or 2, preferably 1; X is a direct bond, or O, S or NR.sub.a in which R.sub.a is hydrogen or C.sub.1-6 alkyl, and is preferably a direct bond; Y is >C.dbd.O, >CHOH, --S.dbd.O or --SO.sub.2 ; each of R.sub.5 and R.sub.6 is C.sub.1-6 alkyl, or R.sub.5 and R.sub.6 are linked together and R.sub.5 represents --(Z).sub.m -- where m is 0 or 1 and Z is O, S or NR.sub.7 where R.sub.7 is hydrogen or C.sub.1-6 alkyl, and R.sub.6 represents --(CH.sub.2).sub.9 -- where q is an integer of from 1 to 4, preferably 2 or 3, and in which one or more of the --(CH.sub.2)-- groups is optionally substituted by a C.sub.1-6 alkyl group, is useful for the treatment of pain.

  化合物或其溶剂化物或盐的化学式（I）##STR1##其中：R.sub.1和R.sub.2独立地为氢、C.sub.1-6烷基、C.sub.2-6烯基、C.sub.3-6环烷基或C.sub.4-12环烷基烷基，或者一起形成C.sub.2-8分支或线性聚亚甲基或C.sub.2-6烯基烯基，可选择地被杂原子取代，前提是R.sub.1和R.sub.2不能同时为氢；R.sub.3为氢、C.sub.1-6烷基，优选甲基或乙基，苯基，或者R.sub.3和R.sub.1一起形成--（CH.sub.2）.sub.3--或--（CH.sub.2）.sub.4--基团；p为1、2、3或4，R为化学式（II）##STR2##其中，--（CHR.sub.4）.sub.n--X--基团在与YR.sub.5或R.sub.6的间位或对位上，R.sub.4为氢或C.sub.1-6烷基，优选为氢；n为0、1或2，优选为1；X为直接键，或O、S或NR.sub.a，其中R.sub.a为氢或C.sub.1-6烷基，优选为直接键；Y为>C.dbd.O、>CHOH、--S.dbd.O或--SO.sub.2；每个R.sub.5和R.sub.6为C.sub.1-6烷基，或者R.sub.5和R.sub.6连接在一起，R.sub.5代表--（Z）.sub.m--，其中m为0或1，Z为O、S或NR.sub.7，R.sub.7为氢或C.sub.1-6烷基，R.sub.6代表--（CH.sub.2）.sub.9--，其中q为1到4的整数，优选为2或3，并且其中一个或多个--（CH.sub.2）--基团可选择地被C.sub.1-6烷基取代，用于治疗疼痛。
• Cyclic carboxamide derivatives and their use as analgesics
  申请人：Dr.Lo.Zambeletti S.p.A.

  公开号：US04801585A1

  公开（公告）日：1989-01-31

  A compound of formula (I): ##STR1## or a salt or solvate thereof in which R. CO is an acyl group containing a substituted or unsubstituted carbocyclic or heterocyclic aromatic ring, R.sub.1 and R.sub.2 are independently C.sub.1-6 alkyl or together form a C.sub.3-6 polymethylene or alkylene group, and p is 1, 2, 3 or 4, is useful for treating pain.

  式(I)的化合物：## STR1 ##或其盐或溶剂化物，其中R.CO是含有取代或未取代的碳环或杂环芳香环的酰基，R1和R2是独立的C1-6烷基或共同形成C3-6聚亚甲基或烷基，p为1、2、3或4，可用于治疗疼痛。
• Heterocyclic ethylene diamine compounds and their pharmaceutical
  申请人：Dr. Lo Zambeletti S.p.A.

  公开号：US04999359A1

  公开（公告）日：1991-03-12

  A compound, or a solvate or salt thereof, of formula I: ##STR1## in which: R.CO-- is an acyl group containing a substituted or unsubstituted carbocyclic aromatic or heterocyclic aromatic group; R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl or C.sub.4-12 cycloalkylalkyl groups or together form a C.sub.2-8 branched or linear polymethylene or C.sub.2-6 alkenylene group, optionally substituted with a hetero-atom; R.sub.3 is hydrogen, C.sub.1-6 alkyl, or phenyl or R.sub.3 together with R.sub.1 form a --(CH.sub.2).sub.3 -- or --(CH.sub.2).sub.4 -- group; R.sub.4 is C.sub.1-6 alkyl, or phenyl; R.sub.5 is hydrogen or together with R.sub.4 forms a --(CH.sub.2).sub.n -- group in which n=1, 2 or 3; and `Het` is an optionally substituted single or fused ring heterocyclic group, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from oxygen, nitrogen and sulphur, with the proviso that when, simultaneously, R.sub.1 and R.sub.2 together are linear butylene, R.sub.3 is hydrogen, R.sub.4 is methyl, R.sub.5 is hydrogen and R is 3,4-dichlorophenyl, `Het` is not pyridyl, is useful for the treatment of pain.

  公式I的化合物，或其溶剂合物或盐：##STR1## 其中： R.CO-是含有取代或未取代的碳环芳香基或杂环芳香基的酰基基团；R1和R2独立地是氢，C1-6烷基，C2-6烯基，C3-6环烷基或C4-12环烷基烷基基团，或者一起形成C2-8支链或线性聚亚甲基或C2-6烯亚甲基基团，可选择地带有杂原子；R3是氢，C1-6烷基或苯基，或者R3与R1一起形成--(CH2)3--或--(CH2)4--基团；R4是C1-6烷基或苯基；R5是氢或与R4一起形成--(CH2)n--基团，其中n = 1、2或3；而“Het”是一个含有5至12个环原子并且包含最多4个异原子（氧、氮和硫）的可选择取代的单环或融合环杂环基团，但是当R1和R2同时是线性丁基时，R3是氢，R4是甲基，R5是氢，而R是3,4-二氯苯基时，“Het”不是吡啶基，用于治疗疼痛。
• TRIAZOLOPYRIDAZINES AS KINASE MODULATORS
  申请人：Lu Tianbao

  公开号：US20090098181A1

  公开（公告）日：2009-04-16

  The invention is directed to triazolopyridazine compounds of Formula I: where R 1 , R 5 , R 6 , R 7 , R 8 , and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明涉及式I的三唑并吡嗪化合物：其中R1、R5、R6、R7、R8和A如本文所定义，使用这种化合物作为蛋白酪氨酸激酶调节剂，特别是c-Met的抑制剂，并使用这种化合物来减少或抑制细胞或受体中c-Met的激酶活性，调节细胞或受体中c-Met的表达，并使用这种化合物预防或治疗细胞增殖性疾病和/或与c-Met相关的疾病。本发明还涉及包含本发明化合物的制药组合物以及治疗癌症和其他细胞增殖性疾病的方法。